When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Authors
Keywords
Immunotherapy, Oncogenic addiction, Targeted therapy, <em class="EmphasisTypeItalic ">EGFR</em>, <em class="EmphasisTypeItalic ">ALK</em>, Non-small cell lung cancer
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 20, Issue 7, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-06
DOI
10.1007/s11864-019-0652-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
- (2018) A. Lisberg et al. Journal of Thoracic Oncology
- BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
- (2018) Elizabeth Dudnik et al. Journal of Thoracic Oncology
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.
- (2018) Marcelo Vailati Negrao et al. JOURNAL OF CLINICAL ONCOLOGY
- Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression.
- (2018) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- RET-rearranged lung cancers: Immunophenotype and response to immunotherapy.
- (2018) Joshua K. Sabari et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).
- (2018) Julien Mazieres et al. JOURNAL OF CLINICAL ONCOLOGY
- Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma
- (2018) Masayuki Nagahashi et al. JOURNAL OF SURGICAL RESEARCH
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
- (2018) Diana Miao et al. NATURE GENETICS
- Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
- (2018) J. Remon et al. CANCER TREATMENT REVIEWS
- Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer
- (2017) Xiaomei Gong et al. Journal of Thoracic Oncology
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
- (2017) Minghui Zhang et al. Scientific Reports
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
- (2016) S. Gettinger et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non–Small-Cell Lung Cancer
- (2016) Jae Joon Han et al. Clinical Lung Cancer
- 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC
- (2016) D.L. Gibbons et al. Journal of Thoracic Oncology
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
- (2016) P. Tomasini et al. ONCOLOGIST
- KRAS et adénocarcinome bronchique. Entre déceptions et espoirs
- (2016) N. Guibert et al. REVUE DES MALADIES RESPIRATOIRES
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives
- (2015) N. Guibert et al. CURRENT MOLECULAR MEDICINE
- Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
- (2015) Antonio Calles et al. Journal of Thoracic Oncology
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Smoking, p53 Mutation, and Lung Cancer
- (2014) Don L. Gibbons et al. MOLECULAR CANCER RESEARCH
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis
- (2013) Daquan Meng et al. LUNG CANCER
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Clinical Relevance of KRAS in Human Cancers
- (2010) Sylwia Jančík et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now